Biotechnology firm Ardelyx has reaffirmed its financial guidance for 2026 while outlining an ambitious long-term growth trajectory for its lead product. The company is also making progress on its clinical pipeline with Phase III enrollment targets.
- Confirmed 2026 financial guidance
- Targeting $1 billion in revenue for IBSRELA by 2029